Thalidomide effects in COVID-19
Phase 3
Recruiting
- Conditions
- Covid 19.Covid 19
- Registration Number
- IRCT20110423006257N3
- Lead Sponsor
- Arak University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 66
Inclusion Criteria
Duration of the symptoms less than 10 days
Lymphocyte count less than 1000 per microliter
Quantitative CRP more than 1.5 times normal
Positive pcr test of covid 19
O2 sat less than 93%
Respiratory rate less than 24
Chest CT scan findings compatible with COVID-19 Pneumonia
Exclusion Criteria
History of chronic disease
Pregnant women, lactating women , sexually active premenopausal women
Loss of consciousness
Liver enzymes more than 5 times normal
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Radiological changes of the lung. Timepoint: Before the intervention and two weeks after the intervention. Method of measurement: Pulmonary computed topography scan.;Death rate. Timepoint: Before the intervention and two weeks after the intervention. Method of measurement: observation.;Length of hospitalization. Timepoint: Before the intervention and two weeks after the intervention. Method of measurement: observation.;Blood oxygen saturation. Timepoint: Before the intervention and two weeks after the intervention. Method of measurement: Pulseoxymeter.
- Secondary Outcome Measures
Name Time Method Complete blood count. Timepoint: Before the intervention and two weeks after the intervention. Method of measurement: Paraclinical.;Erythrocyte sedimentation rate. Timepoint: Before the intervention and two weeks after the intervention. Method of measurement: Paraclinical.;Interleukin 6. Timepoint: Before the intervention and two weeks after the intervention. Method of measurement: Paraclinical.;Creatine phosphokinase. Timepoint: Before the intervention and two weeks after the intervention. Method of measurement: Paraclinical.